Jónína Gudmundsdóttir

Avhandlingen er tilgjengelig her! / The doctoral thesis is available here!

Auditoriet er åpent for publikum. Disputasen vil strømmes og et opptak vil være tilgjengelig i et døgn.
The auditorium is open to the public. The defense will still be streamed, and a recording of the disputation will be available for 24 hours.

Prøveforelesning over oppgitt emne starter kl. 09.15 / The trial lecture starts at 09.15
Tittel/Title:  “Bacterial cell shape - how is defined and controlled?
Prøveforelesningen strømmes her / The trial lecture will be streamed here

Disputasen starter kl. 11.15 / The defense starts at 11.15
Disputasen strømmes her / The defense will be streamed here

De som ønsker å opponere ex auditorio kan sende e-post til leder av disputasen Morten Bøhmer Strøm, morten.strom@uit.no, innen kl. 13:00 disputasdagen. 
If you want to oppose ex. auditorio, send an e-mail to leader of defense Morten Bøhmer Strøm, morten.strom@uit.no, before 13:00 on the day of the defence.

Populærvitenskapelig sammendrag av avhandlingen/ Summary of the thesis:
The aim of the thesis has been to look at how drugs used in cancer chemotherapy affect bacteria, more precisely, if they can cause antimicrobioal resistance (AMR) in the gut bacteria Escherichia coli.
I have used classical approaches from the field of microbial evolution to look at if cancer drugs can cause AMR and/or if AMR bacteria grow better in the presence of cancer drugs than normal bacteria. I show with my work that this is indeed the case and have identified multiple cancer drugs that may drive AMR evolution. For the common cancer drug methotrexate (MTX) I have looked deeper into which mechanisms are at play and shown how MTX can cause, and select for, resistance towards the antibiotic trimethoprim. As the results suggest that cancer drugs may be affecting the evolution of AMR at concentrations estimated to be found in the gut during cancer treatment, they indicate a potential complication for patients undergoing chemotherapy.

Veiledere/ Supervisors:
Hovedveileder/Main supervisor:
Professor Pål Jarle Johnsen, Institutt for farmasi, , Det helsevitenskapelige fakultet, UiT Norges arktiske universitet.
Biveiledere/supervisors:
Professor Ørjan Samuelsen, Institutt for farmasi, Det helsevitenskapelige fakultet, UiT Norges arktiske universitet.
Førsteamanuensis Elizabeth Aarag Fredheim, Institutt for farmasi, Det helsevitenskapelige fakultet, UiT Norges arktiske universitet.

Bedømmelseskomité/Defensecomitee:
Seniorforsker Athanasisos Typas, European Molecular biology labratory (EMBL), Germany – 1. opponent.
Lecturer Benjamin Evans, University of East Anglia, Norwich, England – 2. opponent.
Seniorforsker Sybil Akua O. Oboubi, Institutt for farmasi, Det helsevitenskapelige fakultet, UiT Norges arktiske universitet – leder av komité.

Disputasleder/ Leader of defense:
Professor Morten Bøhmer Strøm, Institutt for farmasi, Det helsevitenskapelige fakultet, UiT Norges arktiske universitet.